# Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

> **NCT00090207** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 477 (actual)

## Conditions studied

- Nausea
- Vomiting

## Interventions

- **DRUG:** MK0869, aprepitant / Duration of Treatment: 3 days
- **DRUG:** Comparator: ondansetron / Duration of Treatment: 4 days

## Key facts

- **NCT ID:** NCT00090207
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01-13
- **Primary completion:** 2004-09-30
- **Final completion:** 2004-09-30
- **Target enrollment:** 477 (ACTUAL)
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090207, "Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00090207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*